Bioequivalence Study of Linagliptin 5 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions

The primary objective of this study is to evaluate the **bioequivalence** of Linagliptin 5 mg film-coated tablets in healthy participants under fasting conditions. Bioequivalence studies are crucial in determining whether a generic version of a drug releases its active ingredient into the bloodstream at the same rate and extent as the original branded drug. This is clinically relevant as it ensures therapeutic equivalence, allowing for the safe substitution of the generic product for the branded one without compromising efficacy or safety.

The clinical trial involves a **study population** that includes both male and female participants, with an age range categorized as 3, which typically corresponds to adults. The trial population is noted to include a **vulnerable population**, although specific details regarding the nature of this vulnerability are not provided. The sponsor has not disclosed the total number of participants involved in the study. Participants do not have any specific medical conditions as a prerequisite for inclusion in the trial. Information regarding lifestyle considerations such as diet, physical activity, or habits has not been provided. The sponsor has not given detailed information on the selection criteria for the trial population.

The clinical trial is designed to assess the **bioequivalence** of Linagliptin 5 mg film-coated tablets in healthy participants under fasting conditions. This trial is a Phase 2 study, which is categorized as a randomized, double-blind, controlled trial. The estimated recruitment start date is September 24, 2024, with an anticipated end date of December 20, 2024. The trial does not involve any specific medical condition, as it is conducted with healthy participants.

The sequence of study visits begins with an inclusion visit, also known as the screening visit, where potential participants are evaluated against the inclusion and exclusion criteria to determine eligibility. Following successful screening, participants will be randomized and enrolled in the study. Throughout the trial, there will be scheduled follow-up visits to monitor the participants' health status and adherence to the study protocol. These visits are crucial for collecting data on the pharmacokinetics of the drug under investigation. The trial will conclude with an end-of-study visit, where final assessments are conducted, and participants are debriefed.

The expected length of participant involvement in the study is determined by the trial's duration, which spans approximately three months from the recruitment start date to the end date. Participants may be subject to early termination from the study if they experience adverse events, fail to comply with the study protocol, or withdraw consent. The trial is conducted under strict ethical guidelines to ensure the safety and well-being of all participants.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be included. The data does not contain any information about the **disease** being studied, the trial's main objective, or any other pertinent details that would typically be included in a clinical trial description.

The clinical trial is in Phase 2 and is scheduled to have an estimated recruitment start date of September 24, 2024, with an estimated end date of December 20, 2024. The efficacy of the intervention will be assessed through various parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow standard procedures for Phase 2 trials, focusing on evaluating the efficacy and safety of the intervention. The trial will adhere to rigorous scientific and ethical standards to ensure the reliability and validity of the results. Data collection and analysis will be conducted in accordance with established clinical trial protocols, although specific tools or instruments for efficacy assessments are not mentioned. The trial's design and execution will be aligned with the objectives of Phase 2 studies, which typically aim to provide preliminary data on the intervention's effectiveness and further assess its safety profile.